0B68 Schnell, Matthias J. - Thomas Jefferson University - Thomas Jefferson University

Matthias J. Schnell, PhD

Contact Dr. Schnell

233 South Tenth Street
Bluemle Life Sciences Building, Room 531
Philadelphia, PA 19107-5541

(215) 503-4634
(215) 503-5393 fax

Most Recent Peer-reviewed Publications

  1. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment
  2. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses
  3. Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1Β release in murine dendritic cells
  4. Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine
  5. Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein
  6. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence
  7. Immune Clearance of Attenuated Rabies Virus Results in Neuronal Survival with Altered Gene Expression
  8. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein
  9. Targeted single-neuron infection with rabies virus for transneuronal multisynaptic tracing
  10. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8+ T cell responses to rabies virus
  11. The role of micronutrients in the diet of HIV-1-infected individuals
  12. Proliferating cell nuclear antigen is required for loading of the SMCX/KMD5C histone demethylase onto chromatin
  13. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses
  14. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge
  15. Rabies Virus as a Research Tool and Viral Vaccine Vector
  16. MicroRNA-122: A Therapeutic Target for Hepatitis C Virus (HCV) Infection
  17. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV
  18. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity
  19. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling.
  20. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: Implications for disparate immune system priming pathways